LIM/24 - Centro de Investigação Translacional em Oncologia

O Centro de Investigação Translacional em Oncologia é ligado ao Departamento de Radiologia e Oncologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP).

Linhas de pesquisa: marcadores moleculares em câncer; bases moleculares de tumorigênese, com ênfase em câncer de mama, hepatocarcionoma e melanoma; papel funcional de genes regulados por hormônios esteroides e por vitamina D em câncer de mama; marcadores preditivos à resposta a quimioterapia em câncer de mama, câncer de cabeça e pescoço e melanoma; mecanismos moleculares de quimiossensibilização e quimiorresistência; microRNAs na progressão de câncer de mama; interações celulares no microambiente tumoral como alvo terapêutico; terapias moleculares alvo-dirigidas em oncologia clínica.

Site oficial:


Recent Submissions

  1. The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?

    BIOMEDICINES, v.10, n.2, article ID 400, 41p, 2022

    Natural killer (NK) cells are innate lymphocytes that play an important role in immuno-surveillance, acting alongside other immune cells in the response against various types of malignant tumors and the prevention of metastasis. Since their discovery in the 1970s, they have been thoroughly studie...

  2. The Impact of the CTHRSSVVC Peptide Upon Experimental Models of Trypanosoma cruzi Infection


    Chagas disease (CD), caused by the hemoflagellate protozoan Trypanosoma cruzi, affects more than six million people worldwide and presents an unsatisfactory therapy, based on two nitroderivatives, introduced in clinical medicine for decades. The synthetic peptide, with CTHRSSVVC sequence (PepA), ...

  3. Prognostic value of integrin alpha V expression and localization pattern in invasive breast carcinomas

    NEOPLASIA, v.30, 2022

    Invasion of surrounding stroma is an early event in breast cancer metastatic progression, and involves loss of cell polarity, loss of myoepithelial layer, epithelial-mesenchymal transition (EMT) and remodeling of the extracellular matrix (ECM). Integrins are transmembrane receptors responsible fo...

  4. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil

    BREAST CANCER RESEARCH AND TREATMENT, v.193, n.2, p.485-494, 2022

    Purpose There is a paucity of data on the spectrum and prevalence of pathogenic variants among women of African ancestry in the Northeast region of Brazil. Methods We performed BROCA panel sequencing to identify inherited loss-of-function variants in breast cancer susceptibility genes among 292 B...

  5. Multicriteria decision analysis in health care decision in oncology: a systematic review


    Introduction Multicriteria decision analysis (MCDA) has been used to inform health decisions in health technology assessments (HTA) processes. This is particularly important to complex treatment decisions in oncology. Areas covered Five databases (PubMed, EMBASE, LILACS, Web of Science and CRD's ...

  6. Many hands make light work: CNV of GSTM1 effect on the oral carcinoma risk

    CANCER EPIDEMIOLOGY, v.78, article ID 102150, 6p, 2022

    Background: Genetic alterations of oral squamous cell carcinoma (OSCC) allow the understanding of the oral carcinogenesis and the identification of molecular biomarkers that aid the early diagnosis of the disease. The copy number variation (CNV) of GSTM1 and GSTT1 are promising targets because th...

  7. Platelet-albumin (PAL) score as a predictor of perioperative outcomes and survival in patients with hepatocellular carcinoma undergoing liver resection in a Western center

    SURGICAL ONCOLOGY-OXFORD, v.42, article ID 101752, 7p, 2022

    Background and objectives: Preoperative selection of patients with hepatocellular carcinoma (HCC) who will benefit from resection is highly advisable. The Platelet-Albumin (PAL) score was developed as a predictor of survival and morbidity following HCC resection. However, this has never been test...

  8. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy

    DISEASES OF THE COLON & RECTUM, v.65, n.3, p.333-339, 2022

    BACKGROUND: Clinical complete responders after chemoradiation for rectal cancer are increasingly being managed by a watch-and-wait strategy. Nonetheless, a significant proportion will experience a local regrowth, and the long-term oncological outcomes of these patients is not totally known. OBJEC...

  9. High dose image-guided, intensity modulated radiation therapy (IG-IMRT) for chordomas of the sacrum, mobile spine and skull base: preliminary outcomes

    JOURNAL OF NEURO-ONCOLOGY, v.158, n.1, p.23-31, 2022

    Purpose To report preliminary outcomes of high dose image-guided intensity modulated radiotherapy (IG-IMRT) in the treatment of chordomas of the sacrum, mobile spine and skull base. Methods Retrospective analysis of chordoma patients treated with surgery and/or radiotherapy (RT) in a single terti...

  10. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

    ECANCERMEDICALSCIENCE, v.16, article ID 1369, 14p, 2022

    Background: Preclinical studies have suggested that metformin has anti-tumour effects, likely due to blockage of mammalian target of rapamycin pathway through adenosine monophosphate-activated protein kinase and decreased insulin levels. A retrospective study showed that metformin added to everol...